A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Alogliptin (Primary) ; Insulin; Metformin; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- 07 Jun 2017 Biomarkers information updated
- 12 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 12 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.